# Onychomycosis

Confirm fungal infection before committing patients to prolonged therapy, obtain an adequately proximal subungual specimen, and select topical versus oral treatment by extent, organism, contraindications, interactions, and treatment goals.

**Clinical question:** How should clinicians confirm, treat, and monitor suspected onychomycosis while avoiding inappropriate systemic antifungal exposure?

Updated: 2026-09-15T23:41:44.423887+00:00

## What matters in practice
- Before prolonged antifungal treatment, obtain mycologic confirmation because traumatic onycholysis, psoriasis, lichen planus, and trachyonychia can mimic onychomycosis. [8][21]
- For distal-lateral disease, sample the most proximal affected subungual material rather than distal detached plate; viable fungi are concentrated near the proximal edge of nail-plate attachment. [10][24]
- Nail clipping histology with PAS is the most sensitive commonly used single test; culture has lower sensitivity but can identify the causative organism. [7][9][12]
- For dermatophyte onychomycosis requiring systemic treatment, oral terbinafine 250 mg daily for 6 weeks for fingernails or 12 weeks for toenails is FDA-labeled; chronic or active liver disease is a contraindication. [1]
- Use topical treatment when disease is limited or oral therapy is unsuitable; expect a longer course and lower effectiveness than systemic therapy. [20][22][24]
- Review CYP2D6-mediated interaction risk before terbinafine, particularly with tricyclic antidepressants, SSRIs, atypical antipsychotics, beta blockers, and tamoxifen. [21][23]

## Confirm fungus before selecting treatment

Clinical appearance directs sampling but does not establish the diagnosis.

Test clinically suspected onychomycosis before committing a patient to prolonged treatment, particularly before an oral agent. Nail dystrophy from traumatic onycholysis, psoriasis, lichen planus, trachyonychia, and toe or foot deformity can resemble distal-lateral subungual disease; an incorrect diagnosis exposes patients to unnecessary systemic adverse effects and delays diagnosis of another nail disorder. [8][21]

Use direct KOH microscopy as a rapid first test when an immediate result will change the visit plan. If KOH is negative but clinical suspicion remains high, submit a nail clipping for PAS histology and/or fungal culture rather than treating the negative test as exclusionary; reported KOH sensitivity is variable, and PAS generally outperforms KOH and culture for detecting fungal elements. [18][21]

Add fungal culture when organism identification will alter management, including suspected yeast or nondermatophyte mold infection, atypical morphology, prior treatment failure, or anticipated alternative systemic therapy. A positive PAS confirms fungal invasion but does not identify species; culture provides organism identification but has lower positivity and is slow. [3][7][12]
- Use dermoscopy as an adjunct to select a representative nail and strengthen the differential while awaiting mycologic testing; it does not replace KOH, PAS, culture, or molecular testing. [11][18]
- In distal-lateral subungual onychomycosis, debride detached distal nail and collect subungual debris from the most proximal involved area. Distal plate sampling reduces culture yield. [10][24]
- If KOH is positive, proceed with treatment selection; if KOH is negative and PAS is positive, fungal infection is established but species is not. [7][9][12]

*Common diagnostic options and the management question each answers. [7][9][12][21]*

| Test | Result timing and diagnostic role | Key limitation | When it changes management |
| --- | --- | --- | --- |
| KOH preparation | Minutes; rapid detection of fungal elements. [12][21] | Sensitivity is variable and a negative result does not reliably exclude infection. [18] | A positive result supports treatment at the initial visit; a negative result with persistent suspicion should prompt PAS and/or culture. [21] |
| Nail clipping with PAS histology | Days; highest reported positivity among common outpatient tests and highly sensitive for fungal elements. [7][9][12] | Does not identify fungal species and requires pathology processing. [12] | Useful after negative KOH with persistent suspicion or before systemic therapy when diagnostic certainty is needed. [21] |
| Fungal culture | Weeks; identifies viable organism and can distinguish dermatophytes from other fungi. [3][13] | Lower sensitivity than KOH and PAS; false-negative results occur with inadequate or distal sampling. [7][10] | Use when species identification is likely to affect drug choice or when disease is atypical or refractory. [3] |

## Choose topical versus systemic therapy by extent and constraints

Treatment is elective for some patients and should be tied to expected benefit.

Offer treatment when nail disease causes pain, functional limitation, distress, or creates clinically important risk, including a history of lower-extremity cellulitis or diabetes with additional cellulitis risks such as prior cellulitis, venous insufficiency, or edema. Treatment is not mandatory for every confirmed infection; align the regimen with nail burden, patient preference, interaction risk, and ability to adhere to a prolonged course. [21][24]

Use an oral agent when disease is moderate to severe, involves multiple nails, or when the likelihood of topical penetration is poor. Expert guidance summarized in a clinical review reserves systemic agents for moderate involvement of 20% to 60% of the nail plate and severe involvement above 60%; topical therapy is an option for mild-to-moderate disease at 60% or less or when oral therapy is contraindicated. [24]

For confirmed dermatophyte disease requiring systemic treatment, prescribe terbinafine 250 mg orally once daily for 6 weeks for fingernail onychomycosis or 12 weeks for toenail onychomycosis. Terbinafine is FDA-indicated for dermatophyte onychomycosis and is generally preferred to topical therapy because it is more effective and has a shorter treatment duration. [1][21]

Use topical therapy when infection is limited, systemic drug interactions or hepatic disease preclude terbinafine, or the patient prioritizes avoidance of systemic toxicity. Efinaconazole 10% solution and tavaborole 5% solution are FDA-approved for toenail onychomycosis; ciclopirox 8% lacquer is FDA-approved for fingernail and toenail disease. Topical treatment has negligible systemic interaction risk but requires longer treatment and has limited cure rates relative to oral therapy. [22][24]
- For ciclopirox lacquer, treatment typically lasts 48 weeks and includes weekly removal of residual lacquer, weekly patient debridement, and monthly professional debridement. [24]
- Do not routinely start oral-plus-topical combination therapy initially; systematic-review authors recommend reserving combination treatment for second-line use because the incremental evidence is limited and study methods are heterogeneous. [22]
- Discuss realistic outcomes: reported complete cure rates range from 35% to 55% for terbinafine, 14% to 43% for itraconazole, and 21% to 48% for fluconazole; visible nail normalization lags behind microbiologic clearance. [20]

### When terbinafine is unsuitable

Do not prescribe oral terbinafine to patients with chronic or active liver disease. Evaluate for liver disease before treatment; liver failure requiring transplant or resulting in death has occurred. [1]

If an oral alternative is needed because terbinafine is contraindicated, poorly tolerated, or poses a consequential interaction, itraconazole is FDA-approved and has activity against dermatophytes, yeasts, and nondermatophyte molds. Reported regimens include 200 mg daily for 3 months or 400 mg daily for 1 week followed by 3 weeks off treatment for four pulses. [20]

Fluconazole is commonly used off-label for onychomycosis; reserve its consideration for situations in which an off-label alternative is appropriate after organism, interaction, and patient-specific risk review. [20]

*Treatment selection for confirmed onychomycosis. [1][20][22][24]*

| Clinical situation | Preferred approach | Regimen or practical implication | Important tradeoff |
| --- | --- | --- | --- |
| Confirmed dermatophyte infection requiring systemic therapy | Oral terbinafine. [1][21] | 250 mg orally once daily for 6 weeks for fingernails or 12 weeks for toenails. [1] | Avoid in chronic or active liver disease; review CYP2D6 interaction risk. [1][23] |
| Mild-to-moderate involvement at 60% or less, or oral therapy unsuitable | Topical antifungal. [24] | Efinaconazole 10% or tavaborole 5% for toenails; ciclopirox 8% for finger- or toenails. [22] | Long treatment duration and lower effectiveness than oral therapy. [20][24] |
| Suspected yeast or nondermatophyte mold, atypical disease, or treatment failure | Obtain culture before changing systemic therapy. [3][12] | Consider itraconazole after organism-directed review; reported regimens are 200 mg daily for 3 months or pulse therapy. [20] | Culture may be falsely negative; ensure proximal subungual sampling. [10] |
| Failure of an appropriately selected initial regimen | Reconfirm diagnosis and reassess specimen quality, organism, adherence, and competing nail disease. [8][10][22] | Reserve oral-plus-topical combination treatment for second-line use. [22] | Recurrence and relapse remain common despite treatment. [20] |

## Screen and counsel before oral terbinafine

The pre-prescription review should determine whether terbinafine is safe and whether another agent is needed.

Before terbinafine, evaluate for chronic or active liver disease and review the medication list for CYP2D6-sensitive drugs. Terbinafine inhibits CYP2D6; clinically relevant interaction review is particularly important for tricyclic antidepressants, SSRIs, atypical antipsychotics, beta blockers, tamoxifen, and metoprolol. [1][20][21][23]

Counsel patients to report symptoms compatible with drug reaction, depressive symptoms, or clinically significant adverse effects. The FDA label reports headache, diarrhea, rash, dyspepsia, liver-enzyme abnormalities, pruritus, taste disturbance, nausea, abdominal pain, and flatulence among common adverse reactions; discontinue terbinafine if signs or symptoms of drug reaction occur. [1]

Set expectations before starting therapy: complete cure requires both mycologic clearance and a visually clear nail, and reported cure rates are limited even with oral therapy. Relapse has been reported as high as 25%, and recurrence estimates range from 6.5% to 53%; reassess persistent dystrophy with repeat mycologic testing rather than reflexively extending or repeating systemic therapy. [20]
- Terbinafine 250 mg tablets may be taken without regard to food. [23]
- For a patient taking metoprolol or another consequential CYP2D6 substrate, avoid assuming that terbinafine is the default oral option; consider an organism-informed alternative or topical treatment. [20][23]
- A normal-appearing nail is not an appropriate early endpoint during treatment because nail growth is required for visible replacement of diseased plate. Complete cure should not be judged solely during the medication course. [20]

*Terbinafine pre-treatment and follow-up decisions. [1][20][21][23]*

| Decision point | Action | Interpretation or next step |
| --- | --- | --- |
| Before prescribing | Evaluate for chronic or active liver disease. [1] | Chronic or active liver disease is a contraindication to oral terbinafine. [1] |
| Medication reconciliation | Review CYP2D6 substrates and psychotropic, beta-blocker, and tamoxifen exposure. [21][23] | If interaction risk is consequential, choose a different strategy rather than automatically prescribing terbinafine. [20] |
| During treatment | Ask about rash, taste disturbance, gastrointestinal effects, mood symptoms, and symptoms of drug reaction. [1] | Discontinue terbinafine if signs or symptoms of drug reaction occur. [1] |
| Persistent or recurrent dystrophy | Repeat mycologic assessment and reconsider alternative diagnoses, sampling quality, and organism. [8][10][20] | Do not equate residual abnormal appearance with proven active dermatophyte infection. [20] |

## Approach apparent treatment failure systematically

Failure should trigger diagnostic reassessment before drug escalation.

When a nail remains abnormal after an adequate course, first distinguish slow outgrowth from active infection. Because complete cure requires mycologic and clinical clearance and relapse or recurrence is common, obtain repeat KOH, PAS, and/or culture from a properly collected proximal subungual specimen before repeating systemic treatment. [10][20]

A negative culture alone does not reliably exclude persistent infection because culture is less sensitive than PAS and is vulnerable to poor sampling. If repeated testing does not confirm fungus, redirect the workup toward mimics such as traumatic onycholysis, psoriasis, lichen planus, or trachyonychia rather than exposing the patient to serial antifungal courses. [7][8][9][12]

If culture identifies a nondermatophyte mold or yeast, or if disease is atypical or recalcitrant, use the identified organism to reassess drug selection. Itraconazole has broader reported activity against dermatophytes, yeasts, and nondermatophyte molds, whereas terbinafine is FDA-indicated specifically for dermatophyte onychomycosis. [1][20]
- Reassess adherence before labeling topical treatment ineffective; topical regimens are prolonged and adherence is a recognized limitation. [24]
- Consider second-line combination therapy only after confirmation of ongoing infection and review of initial-treatment adequacy. [22]
- Do not rely on dermoscopy alone to document persistence or cure; it is an adjunct, not a substitute for mycologic testing. [11]

*Next steps after inadequate response. [7][8][10][20][22]*

| Observed problem | Most useful next action | Why it matters |
| --- | --- | --- |
| Persistent dystrophic nail after therapy | Repeat mycologic testing using proximal subungual material. [10][20] | Separates residual nail damage or delayed outgrowth from persistent infection. [20] |
| Negative culture but high clinical suspicion | Obtain PAS histology and reassess collection site. [7][9][10] | PAS is more sensitive than culture, and distal sampling lowers culture sensitivity. [7][10] |
| Repeated negative fungal studies | Evaluate for traumatic, inflammatory, and other nonfungal nail disorders. [8] | Avoids repeated unnecessary antifungal exposure. [8] |
| Confirmed infection after appropriate monotherapy | Review organism, adherence, drug interactions, and second-line combination options. [20][22] | Combination therapy should not be routine first-line management. [22] |

## References
1. These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS.
      
      
      TERBINAFINE tablets, for oral use
      
      
      Initial U.S. Approval: 1992 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34221c17-0d8c-4b56-8af3-c74efab4599e&amp%3Btype=display
2. Cost-effectiveness of Confirmatory Testing Before ... — jamanetwork.com — https://jamanetwork.com/journals/DERM/articlepdf/2475012/doi150055.pdf
3. S1 Guideline onychomycosis - Nenoff - 2023 - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ddg.14988
4. British Association of Dermatologists' guidelines for the ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358
5. Onychomycosis: a review - Gupta - 2020 - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16394
6. What can GP data tell us about the treatment of onychomycosis in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.84
7. Comparison of diagnostic methods in the evaluation of onychomycosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962203014804
8. Accuracy of Dermoscopy as a Point-of-Care Tool... : Journal of the Philippine Dermatological Society — journals.lww.com — https://journals.lww.com/jpds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01671546-202511000-00002
9. Comparative Evaluation of Potassium Hydroxide Mount, Fungal ... : Indian Journal of Dermatopathology and Diagnostic Dermatology — journals.lww.com — https://journals.lww.com/ijdd/fulltext/2021/08010/comparative_evaluation_of_potassium_hydroxide.2.aspx
10. Onychomycosis: An evaluation of three sampling methods - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962298702816
11. Dermoscopy of Onychomycosis for the Podiatrist - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S089184222100046X
12. Methods for Diagnosing Onychomycosis: A Comparative Study... : Dermatologica Sinica — journals.lww.com — https://journals.lww.com/ders/fulltext/2019/37020/methods_for_diagnosing_onychomycosis__a.1.aspx
13. Diagnosis of onychomycosis made simple - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962299703919
14. [PDF] Topical Antifungal Prescribing for Medicare Part D Beneficiaries - CDC — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7301-H.pdf
15. Traitements topiques et à l'aide de dispositifs pour les ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/references/fr
16. [PDF] List of Publications Using Data from NAMCS and NHAMCS - CDC — www.cdc.gov — https://www.cdc.gov/nchs/media/pdfs/2024/08/namcs_nhamcs_publication_list.pdf
17. Vital and Health Statistics; Series 11, No. 212 (11/78) — www.cdc.gov — https://www.cdc.gov/nchs/data/series/sr_11/sr11_212.pdf
18. Diagnosing Onychomycosis: What’s New? - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146047
19. [PDF] Confocal Microscopy in Clinical and Surgical Dermatology — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/190218/cdc_190218_DS1.pdf
20. Onychomycosis: Old and New - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10219498
21. Onychomycosis: Rapid Evidence Review - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=34652111
22. Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8949799
23. Terbinafine - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK545218?report=reader
24. Introduction - Clinical Review Report: Efinaconazole (Jublia) - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK543985

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.